Comparative Pharmacology
Head-to-head clinical analysis: AZMACORT versus BUDESONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZMACORT versus BUDESONIDE.
AZMACORT vs BUDESONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to produce anti-inflammatory and immunosuppressive effects.
Budesonide is a corticosteroid with potent glucocorticoid activity. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting pro-inflammatory cytokines and leukocyte migration.
Two inhalations (200 mcg) three to four times daily or four inhalations (400 mcg) twice daily via oral inhalation.
Inhaled: 400-800 mcg/day in 2 divided doses for asthma; oral controlled ileal release: 9 mg once daily for Crohn's disease; intranasal: 256 mcg/day in 2 sprays per nostril once daily for allergic rhinitis.
None Documented
None Documented
Clinical Note
moderateBudesonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Gatifloxacin."
Clinical Note
moderateBudesonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Rosoxacin."
Clinical Note
moderateBudesonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Levofloxacin."
Clinical Note
moderateBudesonide + Trovafloxacin
Terminal elimination half-life of 3-4 hours for the inhaled route; prolonged in hepatic impairment.
2-3.6 hours (terminal elimination half-life); due to high hepatic clearance, systemic half-life is short, limiting systemic exposure.
Primarily fecal (60-80%) and renal (10-20%) as metabolites; unchanged drug <5% in urine.
Primarily hepatic metabolism via CYP3A4; metabolites excreted in feces (~60%) and urine (~10-15%). Renal excretion of unchanged drug is negligible (<2%).
Category C
Category A/B
Inhaled Corticosteroid
Inhaled Corticosteroid
"The risk or severity of adverse effects can be increased when Budesonide is combined with Trovafloxacin."